Back to Search
Start Over
Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients.
- Source :
-
Inflammation research : official journal of the European Histamine Research Society ... [et al.] [Inflamm Res] 2023 May; Vol. 72 (5), pp. 895-899. Date of Electronic Publication: 2023 Mar 14. - Publication Year :
- 2023
-
Abstract
- Objective: To evaluate whether colchicine treatment was associated with the inhibition of NLRP3 inflammasome activation in patients with COVID-19.<br />Methods: We present a post hoc analysis from a double-blinded placebo-controlled randomized clinical trial (RCT) on the effect of colchicine for the treatment of COVID-19. Serum levels of NOD-like receptor protein 3 (NLRP3) inflammasome products-active caspase-1 (Casp1p20), IL-1β, and IL-18-were assessed at enrollment and after 48-72 h of treatment in patients receiving standard-of-care (SOC) plus placebo vs. those receiving SOC plus colchicine. The colchicine regimen was 0.5 mg tid for 5 days, followed by 0.5 mg bid for another 5 days.<br />Results: Thirty-six patients received SOC plus colchicine, and thirty-six received SOC plus placebo. Colchicine reduced the need for supplemental oxygen and the length of hospitalization. On Days 2-3, colchicine lowered the serum levels of Casp1p20 and IL-18, but not IL-1β.<br />Conclusion: Treatment with colchicine inhibited the activation of the NLRP3 inflammasome, an event triggering the 'cytokine storm' in COVID-19.<br />Trial Registration Numbers: RBR-8jyhxh.<br /> (© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
Details
- Language :
- English
- ISSN :
- 1420-908X
- Volume :
- 72
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Inflammation research : official journal of the European Histamine Research Society ... [et al.]
- Publication Type :
- Academic Journal
- Accession number :
- 36917217
- Full Text :
- https://doi.org/10.1007/s00011-023-01718-y